|
Jul 29
|
Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income
|
|
Jul 29
|
Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.
|
|
Jul 29
|
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
|
|
Jul 29
|
Bain leads $300M investment in startup built on Bristol Myers immune drugs
|
|
Jul 28
|
Bristol Myers, Bain Capital form new company to develop immunology drugs
|
|
Jul 28
|
Bristol Myers Squibb and Bain Capital Form New Immunology Company
|
|
Jul 28
|
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
|
|
Jul 28
|
Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
|
|
Jul 28
|
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
|
|
Jul 28
|
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
|
Jul 28
|
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
|
|
Jul 28
|
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
|
|
Jul 28
|
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
|
|
Jul 28
|
Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)
|
|
Jul 25
|
Biotech Is Booming, and This Undervalued REIT Stands to Gain
|
|
Jul 25
|
Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 25
|
Bristol Myers shuffles its executive ranks with new CMO
|
|
Jul 25
|
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
|
|
Jul 25
|
2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky
|